Competing interests

Mazyar Shadman reports Consulting, Advisory Boards, steering committees or data safety monitoring committees: Abbvie, Genentech, AstraZeneca, Janssen, Beigene, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Mustang Bio, Fate therapeutics, Nurix, Merck. Research Funding: Mustang Bio, Genentech, AbbVie, Beigene, AstraZeneca, Genmab, Morphosys/Incyte, Vincerx .Stock options: Koi Biotherapeutics. Employment: Bristol Myers Squibb (spouse). Peter Riedell has served as a consultant and/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, CVS Caremark, Genmab, BeiGene, Janssen, and Pharmacyclics. He has received honoraria from Novartis. Research support from BMS, Kite Pharma, Novartis, MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech, and Tessa Therapeutics. Ajay K. Gopal. Research Funding: Merck, I-Mab bio, IgM Bio, Takeda, Gilead, Astra-Zeneca, Agios, Janssen, BMS, SeaGen, Teva, Genmab. Consultancy/Honoraria: Incyte, Kite, Morphosys/Incyte, ADCT, Acrotech, Merck, Karyopharm, Servier, Beigene, Cellectar, Janssen, SeaGen, Epizyme, I-Mab bio, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi, Scitek. Stock Options: Compliment Corporation. Matthew J Frigault repots consulting and advisory roles for Kite/Gilead, BMS, Novartis, JnJ/Legend. Research funding from Arcellx, Kite/Gilead, Novartis, Incyte. Jonathan Brammer receives research funding from BMS, Incyte and consulting fee from DrenBio, Kymera. Reid Merryman: Advisory board: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Inteillia, Epizyme.Consulting: Alphasights, DG Medicine.Institutional research funding: Merck, Bristol Myers Squibb, Genmab, Genentech/Roche. Aleksandr Lazaryan : Consultancy, honoraria, scientific advisory board: Sanofi. Ron Ram: Honoraria: Novartis, Gilead, Takeda, BMS, MSD, Sanofi. Mark Hertzberg: Advisory/honoraria for the following: Takeda, Janssen, Roche, Otsuka, Beigene, Gilead. Farrukh Awan has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellecter Bisosciences, Loxo Oncology, Adaptive Biotechnologies and received research funding from Pharmacyclics. Nirav Shah reports participation on advisory boards and/or consultancy for Kite Pharma, BMS-Juno, Miltenyi Biotec, Lilly Oncology, Epizyme, Incyte, Novartis, Seattle Genetics, Abbvie, and Galapagos. He has research funding, travel support, and honoraria from Lilly Oncology and Miltenyi Biotec. In addition, N.S. is on a scientific advisory board for Tundra Therapeutics. Mohamed A. Kharfan-Dabaja : Research/grant from Novartis, BMS and Pharmacyclics. Alex F. Herrera received research funding and consultancy from Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, ADC Therapeutics. Research finding from KiTE Pharma and Gilead Sciences and consultancy from Karyopharm, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, Abbvie, Allogene Therapeutics Craig Sauter has served as a paid consultant for: Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme, Cargo Therapeutics, Affimed and NKARTA. Mehdi Hamadani reports research support/Funding: Takeda Pharmaceutical Company; ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, Genmab. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. Other authors did not report a COI.

Ethics approval and consent to participate

All patients included in this analysis have provided written consent for research. The Institutional Review Board of MCW have approved this study. Ethics committee approval is not applicable to this study.